arrow-circle-full-right arrow-circle-full-up arrow-circle-up arrow-down arrow-right calendar calendar-done facebook flickr home linkedin login pin reload search share signin star twitter video video youtube nav star-plus info signout double-arrow arrow-up checked
Healthcare & Life Sciences

FT Pharma Pricing and Value Summit

Navigating the Market Access Landscape

New York |
Speakers include:
Susan Shiff

Susan Shiff

Merck

Leonard Schleifer

Leonard Schleifer

Regeneron

Kristin Bass

Kristin Bass

Pharmaceutical Care Management Association

Overview

The American healthcare landscape is brimming with uncertainty. Pressures and priorities vary among stakeholders but whether it’s pharma, payer, PBM, provider or patient, everyone is looking for VALUE.

The FT Pharma Pricing and Value Summit will discuss the future of pharmaceutical pricing and market access in an evolving healthcare environment. Topics on agenda include the politics of drug pricing, the rise of real-world evidence, the role of pharmacy benefit managers and what value means to different stakeholders.

fallback
fallback Add to my Calendar 09/13/2018 08:00:0009/13/2018 16:30:00trueFT Pharma Pricing and Value SummitThe American healthcare landscape is brimming with uncertainty. Pressures and priorities vary among stakeholders but whether it’s pharma, payer, PBM, provider or patient, everyone is looking for VALUE.The FT Pharma Pricing and Value Summit will discuss the future of pharmaceutical pricing and market access in an evolving healthcare environment. Topics on agenda include the politics of drug pricing, the rise of real-world evidence, the role of pharmacy benefit managers and what value means to different stakeholders.FT-Pharma-Pricing-and-Value-Summit471733c6ef2ccb59930f856ef3e642ddMM/DD/YYYY

Speakers (13)

Susan Shiff

Susan Shiff

Senior Vice President, Center for Observational and Real-World Evidence
Merck

Susan Shiff joined Merck in 2014 as Senior Vice President and head of the CORE organization. CORE links together epidemiologists, health economists, outcomes and health services researchers and others involved in health policy research across all of Merck, with the goal of providing health technology assessment agencies and those involved in formulary decisions with the best available information on the value our medicines provide.  

Prior to joining Merck, Dr Shiff was the Global Vice President, Health Economics Research and Evidence Based Medicine at Teva, Inc. Prior to Teva, she spent seven years at Pfizer, including several years as Vice President in the areas of outcomes research, epidemiology, health economics (including pricing) and global market access, both for the primary care business unit, and for emerging markets/established products business unit.  

Dr Shiff has also led a risk management group and US HEOR group at Roche and spent four years at the U.S. Centers for Disease Control and Prevention (CDC). She received her PhD degree from UCLA, and an MBA degree from Cornell University.

Leonard Schleifer

Leonard Schleifer

President and CEO
Regeneron

Leonard Schleifer is the longest serving CEO of a major US biotechnology company. He founded Regeneron Pharmaceuticals in 1988, with Eric Shooter, a leading researcher in the area of nerve growth factors, and Alfred G. Gilman, who received the 1994 Nobel Prize in Medicine for Physiology. Prior to starting Regeneron, he was Assistant Professor at the Cornell University Medical College in the Departments of Neurology and Neurobiology. Dr Schleifer, together with George Yancopoulos, Chief Scientific Officer and a Founding Scientist of the company, have grown Regeneron over 25 years from a tiny start-up to an over $40 billion market cap company with four FDA-approved drugs - PRALUENT ® (alirocumab) Injection, EYLEA ® (aflibercept) Injection, ZALTRAP ® (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST ® (rilonacept) Injection. Under Dr Schleifer’s leadership, the company has established key business collaborations and developed industry- leading technologies for drug discovery and development, resulting in a robust pipeline of monoclonal antibody candidates in areas of high unmet need. In 2011, Dr Schleifer was selected as New York Region Entrepreneur of the Year in Healthcare by Ernst & Young and was appointed by New York Governor Andrew Cuomo Co-Chair of the Mid-Hudson Region Economic Development Council.
Dr Schleifer graduated Phi Beta Kappa and summa cum laude from Cornell University and was awarded his MD and PhD in Pharmacology from the University of Virginia. He is Certified in Neurology by the American Board of Psychiatry and Neurology.

Kristin Bass

Kristin Bass

Senior Vice President, Policy and Federal Affairs
Pharmaceutical Care Management Association

Kristin Bass is the Senior Vice President of Policy and Federal Affairs at the Pharmaceutical Care Management Association. In this role, she leads PCMA’s strategic development of the industry’s legislative policies. Ms Bass joined PCMA from the Senate Finance Committee staff, where she served as Health Policy Advisor to Ranking Minority Member Chuck Grassley (R-IA), with responsibility for private plan options in Medicare and commercial insurance issues.

Previously, Ms Bass was the Senior Vice President for Policy at the Healthcare Leadership Council, where she led efforts on health IT, privacy, and quality improvement. Prior to that, she headed WellPoint, Inc.‘s Federal Affairs office and before that, the federal lobbying team at the American Association of Health Plans (now AHIP). She holds a BA and an MBA from Yale University.

Robert E. Andrews

Robert E. Andrews

CEO
Health Transformation Alliance

Robert E. Andrews currently serves as the CEO of the Health Transformation Alliance (HTA).

As CEO of the HTA, Mr Andrews oversees the strategic direction of 40+ major corporations who have come together in an alliance to do one thing: fix our broken healthcare system. Formed by 4 founding members in September 2015, the HTA has grown to include more than 40 of our nation’s leading employers, who collectively are responsible for more than 7 million employees, dependents and retirees and an annual health care spend of $26 billion. Through Mr Andrews’ leadership, the HTA has launched value-driven solutions specifically designed to improve patient care and economic value through world class data & analytics, path-breaking pharmaceutical solutions, high quality medical networks and robust consumer engagement initiatives.

Mr Andrews previously led the Government Affairs practice at Dilworth Paxson law firm for two years before joining the HTA.

Prior to private practice, Mr Andrews served as a Member of the United States House of Representatives for nearly 24 years. Upon his departure from the Congress, President Barack Obama praised Andrews’ service as “an original author of the Affordable Care Act...and a vital partner in its passage and implementation,” and cited his “tenacity and skill” in representing the people of New Jersey.

Alan Balch

Alan Balch

Chief Executive Officer
Patient Advocate Foundation
Marc Boutin

Marc Boutin

Chief Executive Officer
National Health Council
Sarah Emond

Sarah Emond

Executive Vice President and Chief Operating Officer
Institute for Clinical and Economic Review (ICER)

Sarah Emond leads the strategic planning and operations of the Institute for Clinical and Economic Review(ICER), a leading non-profit health policy research organisation, as Executive Vice President and Chief Operating Officer.  In that role, she is responsible for overseeing ICER’s public programs, communications, operations, and finances.

Prior to joining ICER, Ms Emond spent time as a communications consultant, with six years in the corporate communications and investor relations department at a commercial-stage biopharmaceutical company, and several years with a healthcare communications firm. She began her healthcare career in clinical research at Beth Israel Deaconess Medical Center in Boston.

A graduate of the Heller School for Social Policy and Management at Brandeis University, Ms Emond holds a Master of Public Policy degree with a concentration in health policy.  She also received a Bachelor’s degree in Biological Sciences from Smith College.

Christoph Glaetzer

Christoph Glaetzer

Vice President, Global Market Access
Janssen

Christoph Glaetzer is a trained health economist with more than 20 years global experience in the development and implementation of pharmaceutical market access and commercialization strategies. He is currently Vice President of Strategic Marketing and Market Access for the Asia Pacific and Vice President of Global Market Access for Emerging Health Care Systems at Janssen Pharmaceutica. Christoph is a recognised international thought leader and speaker on healthcare policy and pharmaceutical market access aspects as well as a Champion of innovative access and equity-based tiered pricing strategies. He has represented Janssen/Johnson & Johnson at wide variety of international forums and initiatives.

Jeff Myers

Jeff Myers

President and CEO
Medicaid Health Plans of America

Jeff Myers is the President and CEO of Medicaid Health Plans of America (MHPA), the leading trade association for Medicaid managed care organizations. He serves as the spokesperson for the managed Medicaid industry before Congress, the executive branch, states, and the media, demonstrating the value of Medicaid managed care and leading advocacy efforts for industry policy priorities. Prior to MHPA, Mr Myers was Senior Vice President of Policy and Government Relations at the American Health Care Association, represented the pharmaceutical companies Cephalon, Biogen Idec, Pharmacia, and Hoffman-LaRoche before the legislative and executive branches, and served as US Representative Fred Upton’s Legislative Director and Health Staff for the Energy and Commerce Health Subcommittee. He also worked for US. Representative Alex McMillan where he led Health Staff during consideration of the Health Security Act. Mr Myers received his MBA from Duke’s Fuqua School of Business and his Bachelor’s degree from Rhodes College.

Mark Nagy

Mark Nagy

Vice President, Global Patient Outcomes and Real World Evidence
Eli Lilly
Robert Popovian

Robert Popovian

Vice President, US Government Relations
Pfizer

Robert Popovian is Vice President, US Government Relations at Pfizer Inc. He brings more than two decades of experience in numerous facets of biopharmaceutical and health care industry with a strong track record of expertise, innovation and results in Health Care Policy and Economics, Government Relations, Medical Affairs, and Strategic Planning.

Dr Popovian has published and presented extensively on the impact of biopharmaceuticals and health policies on health care costs and clinical outcomes, including authorship in clinical and healthcare delivery journals and published expert source in First Word, Los Angeles Times, USA Today, Managed Healthcare Executive, Pink Sheet and Bloomberg News amongst many others. He also writes a monthly column published in Morning Consult regarding health policy and economic issues relevant to the biopharmaceutical industry. He is a frequent speaker at healthcare policy and medical conferences on topics such as payment and delivery reform, biosimilars, policies that enable biopharmaceutical innovation and health economics. He currently serves as a board member for the Global Healthy Living Foundation.

Dr Popovian completed his Doctorate in Pharmacy and Masters of Science in Pharmaceutical Economics and Policy degrees at the University of Southern California with honors. The degree in Pharmaceutical Economics and Policy was the first one conferred by an accredited university in the US. He has also completed a residency in Pharmacy Practice/Adult Internal Medicine and Infectious Diseases at the Los Angeles County – University of Southern California Hospital where he was the head resident pharmacist (primary area of research: gram negative bacteremia) and a fellowship in Pharmaceutical Economics and Policy at University of Southern California (primary area of research: payment reform). 

Michael  Rea

Michael Rea

Founder and Chief Executive Officer
Rx Savings Solutions

Michael Rea founded Rx Savings Solutions in 2008 after routinely witnessing consumers struggling to pay for their medications. He noticed quickly at that time that consumers were paying much more than they needed to, which was attributable to a lack of information available to them. He set out on his mission to arm consumers with this information and add efficiency and transparency back into the world of pharmacy. Dr Rea has been involved with research surrounding pharmacy transparency for over 10 years. He received his Doctor of Pharmacy degree from Creighton University.

Nathan White

Nathan White

Senior Vice President, Integrated Access and Outcomes Solutions
ICON Access, Commercialisation and Communications

For more than 16 years, Nathan White has been offering clients advice and solutions on global, US, and European market access and reimbursement challenges. He began his career at Express Scripts, working in leadership, field-based, and internal operational roles in the specialty pharmacy and reimbursement support program divisions. He spent more than five years designing and implementing reimbursement operational solutions at PAREXEL Consulting and Syneos Health, before shifting into global access/HEOR consulting and value communications roles as Director of Market Access at Nucleus Global, Managing Director and Head of Market Access at eMAX Health Systems, and Global Practice Lead at ApotheCom Access Pathways and Outcomes.

fallback

Chair and moderators (2)

David  Crow

David Crow

Senior US Business Correspondent
Financial Times

David Crow is a Senior US Business Correspondent for the Financial Times, covering telecoms, technology, and pharmaceuticals. He is based in New York. He previously worked on the FT's main news desk in London, where he edited the front page of the print edition. Before joining the FT he was Managing Editor of City AM, the London financial newspaper.

Mr Crow has an MA in English Literature from the University of Glasgow.

Sarah  Neville

Sarah Neville

Global Pharmaceuticals Editor
Financial Times

Sarah Neville began her career on local and regional newspapers, eventually becoming political editor of the Yorkshire Post. In 1995 she was awarded the Laurence Stern Fellowship on the Washington Post. She joined the Financial Times in 2001 and has since held a series of senior roles, including Weekend News Editor, Analysis Editor, UK News Editor and public policy editor in 2011. She was appointed Pharmaceuticals Correspondent in 2016.

Agenda - 13th Sep

  • 8:00am
    Registration and Refreshments
  • 9:00am
    Opening remarks from FT chair
  • 9:10am
    Keynote: View from the Hill

    Find out what those with political power have in mind for the future of pricing and market access in the US

  • 9:40am
    Pharma CEO interview

     Leonard Schleifer, President and CEO, Regeneron

     Interviewed by David Crow, Senior US Business Correspondent, Financial Times

  • 10:10am
    Panel: Pricing pressures and healthcare reform
    • What could fuel pricing pressures on pharma in the coming months?
    • How could healthcare reform change the market access landscape?
    • What can be done to encourage open dialogue and overcome political barriers?
    • What are the prospects for a shift towards single-payer healthcare in the US?

    Jeff Myers, President and CEO, Medicaid Health Plans of America

    Sarah Emond, Executive Vice President and Chief Operating Officer, Institute for Clinical and Economic Review

    Robert Popovian, Vice President, US Government Relations, Pfizer

  • 10:55am
    Morning refreshments
  • 11:20am
    Payer perspective: Collaborating to increase value and access

    Companies are coming together to strengthen their negotiating position for healthcare coverage. Will this be an effective and sustainable way of reducing drug prices?  

    Robert E. Andrews, CEO, Health Transformation Alliance

  • 11:55am
    Industry analysis: Payer and manufacturer perspectives on ICER impact

    The short and long-term impact of Institute for Clinical and Economic Review (ICER) assessments on payer and manufacturer decision-making surrounding drug pricing, coverage, access, and reimbursement are still not known. ICON will present results and analysis from a 2018 research study of more than 50 payer and manufacturer organisations and their perceptions of ICER’s impact on both the manufacturer and payer communities.

    Nathan White, Senior Vice President, Integrated Access and Outcomes Solutions, ICON Access, Commercialisation and Communications

  • 12:15pm
    Panel: The rise of real world evidence
    • What are the prospects for the application and regulation of real world evidence in pricing models?
    • How is real-world evidence changing the way stakeholders interact?
    • How is technology and data linkage evolving to support the use of real world evidence?
    • How can real world evidence be applied in risk-sharing models?

    Susan Shiff, Senior Vice President, Center for Observational and Real-World Evidence, Merck

    Mark Nagy, Vice President, Global Patient Outcomes and Real World Evidence, Eli Lilly

  • 1:00pm
    Networking lunch
  • 2:00pm
    Fireside chat: A day in the life of a pharmacy benefit manager

    The role of PBMs is multilayered and not always clear to other stakeholders. Find out what it’s really like performing the role of the “middleman”.  

    Kristin Bass, Senior Vice President, Policy and Federal Affairs, Pharmaceutical Care Management Association

  • 2:30pm
    A value-focused voice for patients

    Value-based pricing must show practical and financial benefits for patients in the real world. What is the evidence that this is really happening and what more can be done?

    Marc Boutin, Chief Executive Officer, National Health Council

  • 3:00pm
    Stakeholder exchange: Bridging the value gap

    More needs to be done to align interests across the pricing and market access landscape. In this innovative session, stakeholders will exchange points of view and ideas with a focus on finding win-win solutions to common problems.     

    • How do different stakeholders express and measure value?
    • How can value for patients be increased in a way that is sustainable?
    • Could new players in the market have an impact on pricing?

    Alan Balch, Chief Executive Officer, Patient Advocate Foundation

    Christoph Glaetzer, Vice President, Global Market Access, Janssen

    Michael Rea, Founder and Chief Executive Officer, Rx Savings Solutions

  • 3:45pm
    Keynote: Regulatory view

    Get the low-down on how proposed and pending regulation on pricing and market access could affect various stakeholders.

  • 4:15pm
    Closing remarks from FT chair
  • 4:20pm
    Networking Reception

Why Attend?

  • Engage with industry peers and other stakeholders across the pricing and market access landscape
  • Discuss the commercial impact of proposals for healthcare reform
  • Explore the rise of real-world evidence in pricing models
  • Hear how innovative pricing models are being applied to support next-generation therapies
fallback

Who Attends?

FT Live has a reputation for delivering very senior, board-level audiences to attend a wide range of world-class thought-leadership events across the globe for nearly 40 years.

The FT Pharma Pricing and Value Summit will be attended by:

  • Pharmaceutical companies
  • Pharmacy benefit managers
  • Medical device manufacturers
  • Healthcare providers and insurers
  • Patient representatives and NGOs
  • Healthcare lawyers and management consultants
  • Banks/Financial services providers
  • Software providers
fallback

Fees

Pharmaceutical & Medical Companies

              

Registration Schedule  

Price

Early Bird Rate (Applied until August 15) 

$595.00

Standard Rate (Applied after August 16) 

$695.00

Solution Providers & Professional Services

              

Registration Schedule  

Price

Early Bird Rate (Applied until August 15) 

$1295.00

Standard Rate (Applied after August 16) 

$1495.00

To purchase a ticket, click here.

fallback

Founding Partner (1)

Life science companies face a rapidly evolving landscape, leading to strategic opportunities as well as challenges including the threat of disruption. Huron's life science practice is part of Huron’s continuum of healthcare offerings supporting the development and commercialization of pharmaceutical products and services.

At Huron, we work with life science companies who typically focus on:

  • Developing winning strategies and new innovative business models that go beyond individual assets and capabilities 
  • Building value and making a difference to all stakeholders throughout the healthcare continuum
  • Achieving affordable access to therapies while managing uncertainty around underlying data
  • Harnessing the power of new technologies and approaches such as digital solutions, use of real-world evidence and analytics, and companion diagnostics

Discover how Huron can help you to harness new developments and stay ahead of the curve. 

Corporate and Business Unit Strategy
Research and Development Portfolio Strategy
Market Access and Pricing
Transaction Support and Due Diligence
Asset Commercial Strategy
Organization and Innovation Development
Drug Safety and Regulatory
Digital Solutions and Technology

Lead sponsor (1)

ICON plc is a global provider of outsourced drug development and commercialisation solutions and services to pharmaceutical, biotechnology, medical device, and government and public health organisations. The company specialises in the strategic development, management and analysis of programs that support clinical development. ICON offers a full range of consulting, development and commercialisation services that help clients to accelerate the development of drugs and devices that save lives and improve quality of life.

ICON’s award-winning study execution capabilities have led to the approval of 18 of the world’s top 20 best-selling drugs.

With headquarters in Dublin, Ireland, ICON currently, operates from 97 locations in 38 countries and has approximately 13,380 employees. For further information please visit www.iconplc.com  Follow @iconplc on Twitter.

Supporting Partners (3)

The National Pharmaceutical Council is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation. Founded in 1953 and supported by the nation’s major research-based pharmaceutical companies, NPC focuses on research development, information dissemination, and education on the critical issues of evidence, innovation and the value of medicines for patients.

When members of the Healthcare Businesswomen’s Association (HBA) come together, it’s with a shared purpose: to be a united force for change. We connect diverse groups of both women and men, across all healthcare and life science disciplines.  By taking focused action to advance our mission, we are creating a powerful movement that directly drives professional opportunity and corporate growth.  We believe that by joining forces in the relentless pursuit of gender parity, we are doing more than uniting individuals—we are strengthening the business of healthcare.

FT Health
The essential briefing for decision makers in health

FT Health is a weekly guide to the news and analysis that matters for decision makers in government, healthcare, research, industry and policy-making around the world. Leading specialists curate the best articles from the FT and across the web and make the links between the big issues. FT Health signposts important coverage on topics including infectious and non-communicable disease, public health, healthcare policy and practice, public health, research, development, drugs, vaccines and diagnostics. Straight to your inbox every Friday.

Venue

10 on the Park
60 Columbus Circle
10th Floor
New York 10019

United States of America

Tel: +1 212-484-6600

fallback

CONTACT US

Joe Hames
Sponsorship Opportunities
Financial Times
Ciaran Larkin
Speaking Opportunities
Financial Times
Meredith Vachon
Media Partner & Press Inquiries
Financial Times